Ernexa Therapeutics Inc. (ERNA) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 32.3 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While ERNA currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.31) and Max Pain ($2.22) forces dealer call-delta covering toward $49.61.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Ernexa Therapeutics Inc. (ERNA) surged +6.57% to $2.11, trading at 2% of its 52-week range ($1.84 – $47.25). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation Discussion features Sanjeev Luther, President and Chief Ex
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ERNA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ERNA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Ernexa Therapeutics Inc. (ERNA) ranks #463 by composite RQD confidence (46/100, grade D) and #972 by equity capitalization ($3.4M). Within this direct 5-issuer industry benchmark cohort, ERNA leads on earnings valuation at N/A trailing P/E, while ERNA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. EOCN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with ERNA at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ERNA
ACTIVE
Ernexa Therapeutics Inc. | D | 46/100 | — | — | -35.0% | +6.57% | $3.4M | Benchmark Subject |
| GRI GRI Bio Inc. | D- | 38/100 | — | — | -35.0% | -3.38% | $3.4M | /gri-vs-erna → |
| ONCO Onconetix Inc. | D- | 36/100 | — | 77.6% | -35.0% | -1.99% | $3.5M | /onco-vs-erna → |
| CVKD Cadrenal Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | -0.47% | $3.4M | /cvkd-vs-erna → |
| EOCN Eocene Ltd. | D | 47/100 | — | — | -35.0% | +0.62% | $3.4M | /eocn-vs-erna → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ernexa Therapeutics Inc. (ERNA) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $582.0K , and -100.0% cumulative change since FY2023) , GAAP net income of -$14.1M, operating cash flow of -$7.0M, and free cash flow of -$7.1M (+56.5% YoY). On the balance sheet, ERNA closed FY2025 with $5.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$14.1M | -$7.0M | -$7.1M | $5.8M | — |
| FY2024 (FY) | 2024-12-31 | $582.0K | -$44.5M | -$15.8M | -$16.2M | $5.3M | — |
| FY2023 (FY) | 2023-12-31 | $68.0K | -$21.7M | -$20.4M | -$20.4M | — | — |
As of 2026-11-01, Ernexa Therapeutics Inc. (NASDAQ: ERNA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $2.11 (+6.57% 1D, market cap $3.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ERNA ranks #463 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ERNA carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GRI (GRI Bio Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $3.4M) and ONCO (Onconetix Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M). Among the 5-stock peer group, ERNA leads on earnings multiple (N/A) while ERNA leads on capital efficiency (-35.0% ROIC).
Per ERNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000748592), Ernexa Therapeutics Inc. generated $0 in revenue (-100.0% YoY), -$14.1M in net income, and -$7.1M in free cash flow against $5.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ERNA last traded at $2.11 (+6.57% on volume of 7,284 shares), positioning the stock -36.25% below its 50-day simple moving average ($3.31) and -71.29% below its 200-day simple moving average ($7.35). Across its 52-week range of $1.84 to $47.25, ERNA sits at the 0.6% percentile with a 14-day RSI of 32.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.85 to $2.37).
Why ERNA Stock surged +6.57% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.